Impact of early relapse after auto-SCT for multiple myeloma

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Auto-SCT is an effective therapy for patients with multiple myeloma (MM), but nearly a fifth of these patients relapse within a year of auto-SCT. We studied 494 patients, undergoing auto-SCT within 12 months of diagnosis of MM. Patients were divided into two groups: early relapse (relapse ≤12 months from auto-SCT) and late relapse (either relapsed > 12 months after auto-SCT or disease free at the last follow up). One hundred twenty patients (24%) were in the early relapse and 374 (76%) were in the late-relapse groups. The early relapse group had a significantly shorter median overall survival (OS) from diagnosis (26.6 vs 90.7 months; P <0.001) and from auto-SCT (20.1 vs 82.5 months; P < 0.001). Among the 345 patients who have relapsed after auto-SCT, median OS from relapse was 10.8 months in the early relapse group compared to 41.8 months for the rest (P < 0.001) and was longer with increasing duration of response to the SCT. In multivariate analyses, labeling index ≥1% at transplant, greater than one treatment regimen prior to auto-SCT, and failure to achieve a complete response were predictive of early relapse. Patients who relapse within 12 months of an auto-SCT have a poor outcome and should be offered trials evaluating novel treatment approaches.

Original languageEnglish (US)
Pages (from-to)413-420
Number of pages8
JournalBone Marrow Transplantation
Volume42
Issue number6
DOIs
StatePublished - 2008

Fingerprint

Multiple Myeloma
Recurrence
Survival
Therapeutics
Multivariate Analysis
Transplants

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Impact of early relapse after auto-SCT for multiple myeloma. / Kumar, Shaji K; Mahmood, S. T.; Lacy, Martha; Dispenzieri, Angela; Hayman, S. R.; Buadi, F. K.; Dingli, David M; Rajkumar, S Vincent; Litzow, Mark R; Gertz, Morie.

In: Bone Marrow Transplantation, Vol. 42, No. 6, 2008, p. 413-420.

Research output: Contribution to journalArticle

@article{239cf092e5b04e0481dcd93f1bad47e9,
title = "Impact of early relapse after auto-SCT for multiple myeloma",
abstract = "Auto-SCT is an effective therapy for patients with multiple myeloma (MM), but nearly a fifth of these patients relapse within a year of auto-SCT. We studied 494 patients, undergoing auto-SCT within 12 months of diagnosis of MM. Patients were divided into two groups: early relapse (relapse ≤12 months from auto-SCT) and late relapse (either relapsed > 12 months after auto-SCT or disease free at the last follow up). One hundred twenty patients (24{\%}) were in the early relapse and 374 (76{\%}) were in the late-relapse groups. The early relapse group had a significantly shorter median overall survival (OS) from diagnosis (26.6 vs 90.7 months; P <0.001) and from auto-SCT (20.1 vs 82.5 months; P < 0.001). Among the 345 patients who have relapsed after auto-SCT, median OS from relapse was 10.8 months in the early relapse group compared to 41.8 months for the rest (P < 0.001) and was longer with increasing duration of response to the SCT. In multivariate analyses, labeling index ≥1{\%} at transplant, greater than one treatment regimen prior to auto-SCT, and failure to achieve a complete response were predictive of early relapse. Patients who relapse within 12 months of an auto-SCT have a poor outcome and should be offered trials evaluating novel treatment approaches.",
author = "Kumar, {Shaji K} and Mahmood, {S. T.} and Martha Lacy and Angela Dispenzieri and Hayman, {S. R.} and Buadi, {F. K.} and Dingli, {David M} and Rajkumar, {S Vincent} and Litzow, {Mark R} and Morie Gertz",
year = "2008",
doi = "10.1038/bmt.2008.180",
language = "English (US)",
volume = "42",
pages = "413--420",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Impact of early relapse after auto-SCT for multiple myeloma

AU - Kumar, Shaji K

AU - Mahmood, S. T.

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Hayman, S. R.

AU - Buadi, F. K.

AU - Dingli, David M

AU - Rajkumar, S Vincent

AU - Litzow, Mark R

AU - Gertz, Morie

PY - 2008

Y1 - 2008

N2 - Auto-SCT is an effective therapy for patients with multiple myeloma (MM), but nearly a fifth of these patients relapse within a year of auto-SCT. We studied 494 patients, undergoing auto-SCT within 12 months of diagnosis of MM. Patients were divided into two groups: early relapse (relapse ≤12 months from auto-SCT) and late relapse (either relapsed > 12 months after auto-SCT or disease free at the last follow up). One hundred twenty patients (24%) were in the early relapse and 374 (76%) were in the late-relapse groups. The early relapse group had a significantly shorter median overall survival (OS) from diagnosis (26.6 vs 90.7 months; P <0.001) and from auto-SCT (20.1 vs 82.5 months; P < 0.001). Among the 345 patients who have relapsed after auto-SCT, median OS from relapse was 10.8 months in the early relapse group compared to 41.8 months for the rest (P < 0.001) and was longer with increasing duration of response to the SCT. In multivariate analyses, labeling index ≥1% at transplant, greater than one treatment regimen prior to auto-SCT, and failure to achieve a complete response were predictive of early relapse. Patients who relapse within 12 months of an auto-SCT have a poor outcome and should be offered trials evaluating novel treatment approaches.

AB - Auto-SCT is an effective therapy for patients with multiple myeloma (MM), but nearly a fifth of these patients relapse within a year of auto-SCT. We studied 494 patients, undergoing auto-SCT within 12 months of diagnosis of MM. Patients were divided into two groups: early relapse (relapse ≤12 months from auto-SCT) and late relapse (either relapsed > 12 months after auto-SCT or disease free at the last follow up). One hundred twenty patients (24%) were in the early relapse and 374 (76%) were in the late-relapse groups. The early relapse group had a significantly shorter median overall survival (OS) from diagnosis (26.6 vs 90.7 months; P <0.001) and from auto-SCT (20.1 vs 82.5 months; P < 0.001). Among the 345 patients who have relapsed after auto-SCT, median OS from relapse was 10.8 months in the early relapse group compared to 41.8 months for the rest (P < 0.001) and was longer with increasing duration of response to the SCT. In multivariate analyses, labeling index ≥1% at transplant, greater than one treatment regimen prior to auto-SCT, and failure to achieve a complete response were predictive of early relapse. Patients who relapse within 12 months of an auto-SCT have a poor outcome and should be offered trials evaluating novel treatment approaches.

UR - http://www.scopus.com/inward/record.url?scp=53149104734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53149104734&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.180

DO - 10.1038/bmt.2008.180

M3 - Article

C2 - 18587435

AN - SCOPUS:53149104734

VL - 42

SP - 413

EP - 420

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -